DoW Ovarian Cancer, Clinical Trial Award

The Ovarian Cancer Research Program Clinical Trial Award, solicitation number HT942526OCRPCTA, is a funding opportunity managed by the Defense Health Agency Contracting Activity for the Department of Defense. This initiative supports the rapid implementation of clinical trials designed to improve the treatment or management of ovarian cancer, ranging from small proof-of-concept pilot studies to large-scale efficacy trials. The program has allocated approximately 5.6 million dollars to fund roughly two awards, with a maximum funding ceiling of 2.8 million dollars per award over a period of up to four years. Applicants must be registered in SAM.gov, eBRAP.org, and Grants.gov to be eligible. The submission process involves a pre-application due September 15, 2026, and a final application deadline of October 1, 2026. Evaluation is conducted through a two-tier process: a first-tier technical merit review scoring clinical impact, trial strategy and feasibility, and study team logistics, followed by a second-tier programmatic review to ensure alignment with FY26 OCRP priorities. Key requirements include the disclosure of foreign affiliations for all key personnel and mandatory approval from the DHA R&D Office of Research and Regulatory Compliance for any research involving human or animal subjects. Required documentation includes a five-page Statement of Work, a technical abstract, and a detailed study population recruitment and safety plan.